Simcere Pharmaceutical Group Ltd

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials. The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials. It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein; Enzeshu, a suvemcitug for injection; SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3; SIM0508, a small molecule inhibitor; SIM0505, a CDH6-targeting ADC molecule; SIM0686, an ADC drug targeting FGFR2b; SIM0609, a new antibody-drug conjugate targeting CDH17; SIM0610, a bispecific antibody-drug conjugate; SIM0532, an oral, non-covalent pan-RAS inhibitor; SIM0323; and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial. The company develops SIM0613; SIM0709; SIM0689; SIM0688; SIM0518; SIM0616; SIM0611; SIM0815; SIM0712; SIM0725; SIM0708; SIM0721; and SIM0722 that are in pre-clinical stage. It offers pharmaceutical ingredients; production support facility; consulting and technology; promotion; and property management. The company was founded in 1995 and is headquartered in Nanjing, China.